Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial-Reference-Cited by-同舟云学术

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

Published:2021-11-10 Issue:1 Volume:48 Page:45-55
ISSN:0342-4642
Container-title:Intensive Care Medicine
language:en
Short-container-title:Intensive Care Med

Author:

Granholm Anders^ORCID,Munch Marie Warrer,Myatra Sheila Nainan,Vijayaraghavan Bharath Kumar Tirupakuzhi,Cronhjort Maria,Wahlin Rebecka Rubenson,Jakob Stephan M.,Cioccari Luca,Kjær Maj-Brit Nørregaard,Vesterlund Gitte Kingo,Meyhoff Tine Sylvest,Helleberg Marie,Møller Morten Hylander,Benfield Thomas,Venkatesh Balasubramanian,Hammond Naomi E.,Micallef Sharon,Bassi Abhinav,John Oommen,Jha Vivekanand,Kristiansen Klaus Tjelle,Ulrik Charlotte Suppli,Jørgensen Vibeke Lind,Smitt Margit,Bestle Morten H.,Andreasen Anne Sofie,Poulsen Lone Musaeus,Rasmussen Bodil Steen,Brøchner Anne Craveiro,Strøm Thomas,Møller Anders,Khan Mohd Saif,Padmanaban Ajay,Divatia Jigeeshu Vasishtha,Saseedharan Sanjith,Borawake Kapil,Kapadia Farhad,Dixit Subhal,Chawla Rajesh,Shukla Urvi,Amin Pravin,Chew Michelle S.,Wamberg Christian Aage,Gluud Christian,Lange Theis,Perner Anders

Funder

The Novo Nordisk Foundation

Rigshospitalet's Research Council

Publisher

Springer Science and Business Media LLC

Subject

Critical Care and Intensive Care Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00134-021-06573-1.pdf

Reference28 articles.

1. Haase N, Plovsing R, Christensen S et al (2021) Characteristics, interventions and longer-term outcomes of COVID-19 ICU patients in Denmark – a nationwide, observational study. Acta Anaesthesiol Scand 65:68–75

2. World Health Organization (2021) Coronavirus disease (COVID-19) Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 27 Sep 2021.

3. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group (2020) Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA 324:1330–1341

4. Rochwerg B, Agarwal A, Siemieniuk RA et al (2020) A living WHO guideline on drugs for covid-19. BMJ 370:m3379

5. Munch MW, Granholm A, Myatra SN et al (2021) Higher vs. lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: protocol and statistical analysis plan. Acta Anaesthesiol Scand 65:834–845

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of high versus standard enteral protein provision on functional recovery following intensive care admission: Protocol for a pre-planned secondary Bayesian analysis of the PRECISe trial;Clinical Nutrition ESPEN;2024-02

2. Personalized corticosteroid treatment of patients with severe new coronavirus infection complicated by pneumonia: a prospective comparative study;Annals of Critical Care;2024-01-27

3. Case report: Enhancing prognosis in severe COVID-19 through human herpes virus coinfection treatment strategies;Frontiers in Cellular and Infection Microbiology;2024-01-10

4. Corticosteroid Dosing Level, Incidence and Profile of Bacterial Blood Stream Infections in Hospitalized COVID-19 Patients;Viruses;2024-01-05

5. Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia – a post hoc evaluation of the COVID STEROID 2 trial;The Lancet Regional Health - Southeast Asia;2024-01